ClinicalTrials.Veeva

Menu

An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)

Merck KGaA (EMD Serono) logo

Merck KGaA (EMD Serono)

Status and phase

Completed
Phase 2

Conditions

Schistosomiasis

Treatments

Drug: Biltricide (racemate praziquantel) oral tablets
Drug: Racemate Praziquantel ODT
Drug: Levo Praziquantel ODT

Study type

Interventional

Funder types

Industry

Identifiers

NCT02806232
200661-0005

Details and patient eligibility

About

The Phase II study consisted of two parts, part 1 is open label, randomized, controlled and exploratory dose finding in children aged between 2 and 6 years infected with S. mansoni. Part 2 investigated efficacy and safety with the selected formulation and dosage in S. mansoni infected children aged between 3 months - 2 years.

Enrollment

444 patients

Sex

All

Ages

3 months to 6 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male and female children aged 2 to 6 years (Part 1) and 3 to 24 months (Part 2)

  • S. mansoni positive diagnosis defined as positive egg counts in stool (greater than [>]1 egg/1 occasion) according to World Health Organization (WHO) classification : light (1-99 eggs per gram of faeces), moderate (100-399 eggs per gram of faeces) and heavy (greater than or equal to [>=]400 eggs per gram of faeces) infections

  • Minimum weight of 8.0 kg in 2- to 6-year-old children and of 4.0 kg in 3- to 24-month infants

    • Parents/legal representative ability to communicate well with the Investigator, to understand the protocol requirements and restrictions, and willing their children to comply with the requirements of the entire trial, i.e.

  • To be examined by a study physician at screening and 14-21 days after treatment

  • To provide stool and urine samples at screening, 24 hours and 8 days after treatment, as well as 14-21 days after treatment

  • To provide finger prick blood samples for Pharmacokinetics (PK) studies and blood samples for safety assessments

Exclusion criteria

  • Treatment in the 4 weeks prior to study screening with Praziquantel (PZQ) , other anti-helminthic, antimalarial or anti-retroviral compounds or any other medication that might affect the PK of PZQ such as certain antiepileptics (e.g., carbamazepine or phenytoin), glucocorticosteroids (e.g., dexamethasone), chloroquine, rifampicin or cimetidine
  • For children being breast fed, treatment of the mothers/wet nurses with PZQ in the 3 days prior to administration of Investigational medicinal product
  • Previous history of adverse reactions associated with PZQ treatment
  • Marked increases of the liver transaminases (alanine aminotransferase and/or aspartate aminotransferase) above 3x Upper Limit of Normal (ULN)
  • History of acute or severe chronic disease including hepato-splenic schistosomiasis
  • Fever defined as temperature above 38.0 degree centigrade
  • Debilitating illnesses such as tuberculosis, malnutrition, etc. as well as a medical history of seizures
  • Mixed S. haematobium and S. mansoni infections
  • Findings in the clinical examination of schistosome-infected children participating in the study as performed by the study clinician on the treatment day, that in the opinion of the Investigator constitutes a risk or a contraindication for the participation of the subject in the study or that could interfere with the study objectives, conduct or evaluation
  • Unlikelihood to comply with the protocol requirements, instructions and trial-related restrictions, e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the trial

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

444 participants in 9 patient groups

Part 1, Cohort 1: Biltricide (racemate praziquantel) 20 mg/kg
Experimental group
Description:
Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.
Treatment:
Drug: Biltricide (racemate praziquantel) oral tablets
Part 1, Cohort 2: Biltricide (racemate praziquantel) 40 mg/kg
Experimental group
Description:
Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
Treatment:
Drug: Biltricide (racemate praziquantel) oral tablets
Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg
Experimental group
Description:
Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
Treatment:
Drug: Racemate Praziquantel ODT
Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg
Experimental group
Description:
Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
Treatment:
Drug: Racemate Praziquantel ODT
Part 1, Cohort 5: Levo Praziquantel 30 mg/kg
Experimental group
Description:
Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.
Treatment:
Drug: Levo Praziquantel ODT
Part 1, Cohort 6: Levo Praziquantel 45 mg/kg
Experimental group
Description:
Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.
Treatment:
Drug: Levo Praziquantel ODT
Part 1, Cohort 7: Levo Praziquantel 60 mg/kg
Experimental group
Description:
Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
Treatment:
Drug: Levo Praziquantel ODT
Part 2, Cohort 8: Levo Praziquantel 50 mg/kg
Experimental group
Description:
Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
Treatment:
Drug: Levo Praziquantel ODT
Part 2, Cohort 9: Levo Praziquantel 50 mg/kg
Experimental group
Description:
Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
Treatment:
Drug: Levo Praziquantel ODT

Trial documents
2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems